Table 1: Published clinical vaccination trials of GSK’s conjugate meningococcal vaccines.

VaccineStudyPhaseCountryTarget groupSchedule 𝑁 Publication

NCT00317174Phase IIPhilippinesInfants6, 10, 14 weeks
PS challenge at 10 months
524
217
Gatchalian et al., 2008 [59]*
DTPw-HBV/Hib-MenACISRCTN35754083Phase IIGhanaInfants6, 10, 14 weeks
PS challenge at 12 months
280
260
Hodgson et al., 2008 [60]
NCT00317161 and NCT00317187Phase IIIPhilippines, ThailandInfants2, 4, 6 months1780Kerdpanich et al., 2008 [61]

NCT00135486 and NCT00135564Phase IIGermanyInfants2, 3, 4 months
PS challenge at 12–15 months
520Schmitt et al., 2007 [70]
NCT00323050 and NCT00322335Phase IIISpainInfants2, 4, 6 months
13-14 months
237
358
Tejedor et al., 2007 [62]
Tejedor et al., 2008 [74]
Hib-MenC-TTNCT00263653Phase IIISpainToddlers13-14 months297Carmona et al., 2010 [75]
NCT00258700Phase IIIUK, PolandInfants2, 3, 4 months
12 months
500
476
Pace et al., 2007 [69]
Pace et al., 2008 [73]
Khatami et al., 2011 [76]
NCT00334334
NCT00463437
Phase IIIGermany, Poland, SpainInfants2, 4, 6 months
11–18 months
1548
1437
Wysocki et al., 2009 [80]
Knuf et al., 2009 [71]
NCT00326118Phase IIIAustraliaToddlers12–18 months433Booy et al., 2011 [72]
ISRCTN72858898Phase IVUKChildren6–12 years249Perrett et al., 2010 [77]

NCT00127855Phase IIAustraliaInfants2, 4, 6 months
PS challenge at 11–14 months
407
394
Nolan et al., 2007 [81]
NCT00129116Phase IIBelgium, GermanyInfants2, 3, 4 months
12–18 months
388
221
Habermehl et al., 2010 [68]
Hib-MenCY-TTNCT00129129Phase IIUSInfants2, 4, 6 months
12–15 months
756
498
Marchant et al., 2010 [82]
Marshall et al., 2010 [83]
NCT00134719Phase IIAustraliaInfants2, 4, 6 months
12–15 months
1103
1037
Nolan et al., 2011 [84]
NCT00289783Phase IIIUS, Mexico, AustraliaInfants2, 4, 6 months
12–15 months
4180Bryant et al., 2011 [85]

NCT00196950
NCT00126945
Phase IIBelgium, DenmarkAdolescents
Adults
15–25 years175Østergaard et al., 2009 [86]
NCT00126984Phase IIGermany, AustriaToddlers
 Children
12–14 months
or 3–5 years
508Knuf et al., 2010 [87]
MenACWY-TTNCT00464815
NCT00453986
Phase IIIPhilippines, India, Taiwan + Philippines, LebanonAdolescents
Adults
11–17 years
and 18–55 years
2272Bermal et al., 2011 [88]
NCT00454909Phase IIUSAdolescents
Adults
11–25 years872Baxter et al., 2011 [89]
NCT00474266Phase IIIFinlandToddlers12–23 months1000Vesikari et al., 2011 [90]
NCT00508261Phase IIIAustria, Germany, GreeceToddlers12–23 months793Knuf et al., 2011 [91]

N: Total vaccinated cohort including subjects who received the study vaccine and control vaccines, NCT: Clinical Trial Registry Numbers, ISRCTN: International Standard Randomized Controlled Trial Number, *Number of the publication in the reference list, 1025 subjects from study NCT00464815 (Philippines, India, Taiwan) and 1247 from study NCT00453986 (Philippines, Lebanon), For study NCT00453986 only safety data are summarised here.